MUCOPOLYSACCHARIDOSIS TYPE I (MPS I)

Clinical trials for MUCOPOLYSACCHARIDOSIS TYPE I (MPS I) explained in plain language.

Never miss a new study

Get alerted when new MUCOPOLYSACCHARIDOSIS TYPE I (MPS I) trials appear

Sign up with your email to follow new studies for MUCOPOLYSACCHARIDOSIS TYPE I (MPS I), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Brain-Targeting gene therapy tested for devastating rare disease

Disease control Terminated

This early-stage study is testing a one-time gene therapy called RGX-111 for people with MPS I, a rare genetic disorder that affects the brain. The therapy aims to deliver a working copy of a missing gene directly to the central nervous system to help the brain produce a needed e…

Matched conditions: MUCOPOLYSACCHARIDOSIS TYPE I (MPS I)

Phase: PHASE1, PHASE2 • Sponsor: REGENXBIO Inc. • Aim: Disease control

Last updated Mar 30, 2026 14:28 UTC

MUCOPOLYSACCHARIDOSIS TYPE I (MPS I)

Get alerted when new MUCOPOLYSACCHARIDOSIS TYPE I (MPS I) trials appear

Brain-Targeting gene therapy tested for devastating rare disease